New Data Show Efficacy of Combo Therapy Elbasvir/Grazoprevir for Hepatitis C
October 3rd 2018A new review of clinical trial data show the combination therapy elbasvir/grazoprevir (EBR/GR) has high rates of efficacy for patients with genotypes 1a, 1b, and 4 chronic hepatitis C (HCV) infection.
Read More
Researchers Urge for Removal of HCV Treatment Restrictions for Drug Users
October 2nd 2018In light of new evidence supporting the efficacy of hepatitis C virus (HCV) treatments in individuals who use or inject drugs, researchers are urging the removal of restrictions that prevent recent drug users from accessing lifesaving HCV therapies.
Read More
FDA Approves Antibacterial Treatment for Lung Disease
October 1st 2018The FDA has approved amikacin liposome inhalation suspension (Arikayce, Insmed), for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment.
Read More
FDA Approves Antibacterial Treatment for Lung Disease Through Novel Pathway
September 29th 2018The FDA has approved amikacin liposome inhalation suspension (Arikayce, Insmed), for the treatment of lung disease caused by a group of bacteria in a limited population of patients with the disease who do not respond to conventional treatment.
Read More